ClinicalTrials.gg
RecruitingNCT06734520Updated Dec 16, 2024

Clinical Study of Super Transplantation in the Treatment of Severe β-thalassemia

An interventional study of super-transplantation in 3 severe β -thalassemia pediatric patients. in Thalassemia Majors (Beta-Thalassemia Major) and Haplo-identical Donors, sponsored by Guangzhou Women and Children's Medical Center. Recruiting at 2 sites in China. Open to participants aged 7 Years to 10 Years. Per ClinicalTrials.gov, last updated 2024-12-16.

Sponsored by Guangzhou Women and Children's Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
7 Years to 10 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in beta-Thalassemia with a site in China — 20 open to participants now, 25 under way, 1 of them phase 3. beta-Thalassemia · China.

Planned enrollment
27th of 34
3 · median 10
Started
2024
with 10 others
No phase
13 of 44
4 open now
Primary completion
2029-07
later than 19 of 24 live
Registered
40th of 44
by date
Lead sponsor
1 of 44
Guangzhou Women and Children's Medical Center

Among the 44 studies in beta-Thalassemia with a site in China, this one is the 27th largest by planned enrollment of the 34 interventional ones that give a count, is one of 11 that started in 2024, is one of 13 with no phase, reaches primary completion later than 19 of the 24 other live ones, and was the 40th registered.

beta-Thalassemia

295 studies on the registry are indexed under beta-Thalassemia; 70 are open to participants now.

Browse beta-Thalassemia studies →

Open to participants now

20 of the 44 studies in beta-Thalassemia with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.

This study: 7 Years to 10 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in beta-Thalassemia with a site in China, or all of them as a file.
02

Study summary

This is a single-arm, open label, phase 1 study in subjects with beta-thalassemia. This study will evaluate the safety and efficacy of preconditioning-free super-transplantation on beta-thalassemia pediatric patients.

Read the detailed description

Patient screening:

  1. Two months before transplantation, pediatric patients are evaluated by our center, and the patients meeting the inclusion criteria will be screened into the group.
  2. Investigators and doctors will give detailed information about the benefits and risks of participating in the study, and the informed consents are further signed.

Transplant conduction:

  1. Donor mobilization: HLA-fully matched or haplo-identical donors are mobilized subcutaneously for five days with human granulocyte colony-stimulating factor (G-CSF) and the peripheral blood mononuclear cells (PBMCs) that contain a certain numbers of CD34+ stem cells and CD3+ lymphocytes will be extracted by blood cell separators.
  2. Transplant regimen: Hydroxycarbamide will be used to reduce the total white blood cells before transplant. However, no traditional transplantation conditioning will be performed, including but not limited to busulfan, fludarabine, Cyclophosphamide, ATG, and irradiation. Splenectomy should be performed if the longitudinal diameter of the spleen exceeds the normal value by 4 cm.
  3. Cell infusion: Pediatric patients will be infused with the PBMCs intravenously at day 0.
  4. GVHD prophylaxis: The dosage of immunosuppressants is half of the conventional post-transplantation level, but adjustments to the dosage may be necessary based on specific circumstances.
  5. Infection management: Antibacterial, antifungal medications, and anti-Pneumocystis medications need to be administered during the period of granulocytopenia. The preemptive treatment for cytomegalovirus will be performed when the virus serological test is positive.
03

Conditions studied

  • Thalassemia Majors (Beta-Thalassemia Major)
  • Haplo-identical Donors

Browse trials for

04

Who can participate

Ages eligible
7 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of severe β -thalassemia
  2. Age between 7-10 years old, male and female; Weight \< 40kg
  3. The patient has or does not have an HLA-compatible or semi-compatible donor, but unconditional transplantation or refusal of blood stem cell transplantation; Patients with thalassemia gene therapy without conditions or refusal;
  4. There are fully compatible or incompatible HLA donors, and the physical examination meets the donor conditions;
  5. The patient and family members agree to receive hypertransplant therapy and sign a written prior to the transplant trial.

Exclusion criteria

Exclusion Criteria:

  1. Mental patients;
  2. Participants in other drug clinical trials within the past 1 month;
  3. There are no suitable HLA-incompatible donors.
  4. Other researchers decide that it is not suitable to participate in this researcher.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (estimated)

Study arms

  • Experimental
    Severe β -thalassemia

    Children with β-thalassemia major received super transplantation, and chimerism tests were performed at 3 months, 6 months, 9 months, and 1 year after transplantation to evaluate the safety and effectiveness.

    Drug: super-transplantation in 3 severe β -thalassemia pediatric patients.

Interventions

  • Drugsuper-transplantation in 3 severe β -thalassemia pediatric patients.

    Haplo-identical donors are mobilized with G-CSF and PBMCs that contain CD34+ stem cells and CD3+ lymphocytes will be extracted by blood cell separators. Then the patients will be infused with the PBMC

06

What researchers measure

Primary outcomes

  1. chimeric status

    Detecting the chimerism in recipients' peripheral blood and bone marrow.Chimerism is generally measured in percentages(%)

    Time frame: 1 year after transplantation.

07

Study locations

1 of 2 sites recruiting
  • Guangzhou Women and Children's Medical Center Affiliated to Guangzhou Medical University
    Guangzhou, Guangdong 51000, China
    Active, not recruiting

    Not enrolling at this site.

  • Guangzhou Women and Children's Medical Center Affiliated to Guangzhou Medical University
    Guangzhou, Guangdong, China
    Recruiting
08

References and documents

Publications

  • Ali S, Mumtaz S, Shakir HA, Khan M, Tahir HM, Mumtaz S, Mughal TA, Hassan A, Kazmi SAR, Sadia, Irfan M, Khan MA. Current status of beta-thalassemia and its treatment strategies. Mol Genet Genomic Med. 2021 Dec;9(12):e1788. doi: 10.1002/mgg3.1788. Epub 2021 Nov 5. PubMed 34738740 ↗
  • Shafique F, Ali S, Almansouri T, Van Eeden F, Shafi N, Khalid M, Khawaja S, Andleeb S, Hassan MU. Thalassemia, a human blood disorder. Braz J Biol. 2021 Sep 3;83:e246062. doi: 10.1590/1519-6984.246062. eCollection 2021. PubMed 34495151 ↗
  • Dever DP, Bak RO, Reinisch A, Camarena J, Washington G, Nicolas CE, Pavel-Dinu M, Saxena N, Wilkens AB, Mantri S, Uchida N, Hendel A, Narla A, Majeti R, Weinberg KI, Porteus MH. CRISPR/Cas9 beta-globin gene targeting in human haematopoietic stem cells. Nature. 2016 Nov 17;539(7629):384-389. doi: 10.1038/nature20134. Epub 2016 Nov 7. PubMed 27820943 ↗

Individual participant data

Plan to share: Yes — Share IPD with 5th Medical Center ofA General Hospital

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: The start date is October 2024 and the end date is July 2029

Access criteria: The sponsors and collaborators are able to access the IPD and supporting information, IPD relies on team collaboration , as well as continuous improvement in innovation and efficiency. Participants will share project information, including the project's objectives, statistical datas, and clinical study report.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Jul 2029, 57 months after the start.

Of 29 interventional studies with no phase under beta-Thalassemia, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 69. This study's planned 57 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2024
First posted
Dec 16, 2024
StartActual
Oct 1, 2024
Primary completionEst.
Jul 1, 2029
CompletionEst.
Jul 1, 2029
Last update
Dec 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06734520
Lead sponsor
Guangzhou Women and Children's Medical Center
Responsible party
Sponsor
First posted
Dec 16, 2024
Start date
Oct 1, 2024
Primary completion
Jul 1, 2029 (estimated)
Completion
Jul 1, 2029 (estimated)
Last update
Dec 16, 2024

Study contacts

Hua Jiang, Doctor
Contact
jiang_hua18@sina.cn
86-020-38076501
Hua Jiang, PHD
study director · Guangzhou Medical University Affiliated Women's and Children's Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion